Gaucher Disease clinical trials

Explore recruiting gaucher disease clinical trials.

Recruiting gaucher disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gaucher Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT201) in Subjects with Gaucher Disease (GALILEO-2)

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A 4-part, open-label, multicenter, multinational study of the safety, tolerability, pharmacokinetics, pharmacodynamic, and exploratory efficacy of venglustat in combination with Cerezyme in adult patients with Gaucher disease Type 3 with venglustat monotherapy extension

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Effectiveness of ambroxol in children and adults with Gaucher disease 3: n-of-1 series

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Subjects with Peripheral Manifestations of Gaucher Disease

Germany, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

LEAP2MONO - EFC17215 A phase 3, multicenter, multinational, randomized, double-blind, double-dummy, active-comparator study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease Type 3 (GD3) who have reached therapeutic goals with Enzyme Replacement Therapy (ERT)

Germany, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open label, two cohort (with and without imiglucerase), multicenter study to evaluate pharmacokinetics, safety, and efficacy of eliglustat in pediatric patients with Gaucher disease type 1 and type 3

Spain, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Gaucher Disease trials by city

Gaucher Disease in Toronto Gaucher Disease in Vancouver Gaucher Disease in Montreal Gaucher Disease in Calgary Gaucher Disease in Edmonton Gaucher Disease in Ottawa Gaucher Disease in Winnipeg Gaucher Disease in Quebec City Gaucher Disease in Hamilton Gaucher Disease in Kitchener Gaucher Disease in London Gaucher Disease in Halifax Gaucher Disease in New York Gaucher Disease in Los Angeles Gaucher Disease in Chicago Gaucher Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease